AbbVie (ABBV) News Today

AbbVie Inc. (NYSE:ABBV) saw its shares move today amid a mix of upbeat clinical data, promotional campaigns, and analyst revisions, partly offset by mixed earnings results and a modest pullback in trading. Key developments include:

• Positive Sentiment: Equity research firm William Blair raised AbbVie's Q1 2026 EPS estimate to $3.11, up from $3.00. William Blair Q1 2026 EPS Estimate
• Positive Sentiment: Leerink Partners boosted its Q3 2025 EPS forecast for AbbVie to $3.34 from $3.18. Leerink Partners Q3 2025 EPS Estimate
• Positive Sentiment: AbbVie and Genmab reported promising Phase 3 results for a DLBCL treatment, reinforcing their oncology pipeline. AbbVie and Genmabs Promising Phase 3 Study for DLBCL Treatment
• Positive Sentiment: AbbVie's Ubrogepant Phase 3 study showed encouraging data for menstrual migraine relief. AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief
• Positive Sentiment: AbbVie’s Phase 3 trial of atogepant for menstrual migraine prevention delivered positive interim results. AbbVie’s Promising Phase 3 Study on Atogepant for Menstrual Migraine Prevention
• Positive Sentiment: AbbVie reported eye-opening Rinvoq data in alopecia areata, highlighting expansion potential beyond rheumatoid arthritis. AbbVie Flashes Eye-Opening Results for Rinvoq in Alopecia Areata
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, announced its third annual JUVÉDERM® Day with BOGO gift cards and a $10,000 sweepstakes to drive aesthetic product sales. Get Ready, JUVÉDERM® Day is Calling!
• Positive Sentiment: Allergan Aesthetics unveiled new campaign stories for Natrelle® breast products, aiming to bolster consumer engagement and brand transparency. Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
• Positive Sentiment: In July, TV drug ad spending dropped industry-wide, yet AbbVie’s Skyrizi reclaimed the top spot among advertised brands. TV Drug Ad Spending Plummeted in July, While AbbVie’s Skyrizi Regained the Lead
• Neutral Sentiment: AbbVie’s Q2 2025 results beat revenue forecasts but missed on EPS, underscoring mixed near-term fundamentals. AbbVie Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
• Neutral Sentiment: Zacks highlights rising investor interest in ABBV shares as market watchers track its upcoming catalysts. AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Zacks also flagged AbbVie among two medical stocks with favorable Earnings ESP setups. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Neutral Sentiment: Jim Cramer named AbbVie among his top dividend picks in a recent segment, underscoring its yield appeal. Jim Cramer Says To Buy These 3 Dividend Stocks ASAP
• Neutral Sentiment: Analysts from American Banking News shared varied forecasts for AbbVie's upcoming Q1 earnings, reflecting a broad range of expectations. Research Analysts Offer Predictions for AbbVie Q1 Earnings
• Negative Sentiment: AbbVie's stock traded down amid some profit-taking after these updates. AbbVie Stock Price Down 1.5% – Here’s What Happened